Entries by Rebecca.Mercer@cancercare.on.ca

Article: Is There Evidence in Real-World Evidence?

“Evidence from real-world practice and utilization—outside of clinical trials—is seen to tailor healthcare decision-making more closely to the characteristics of individual patients, and thus as a step towards making healthcare more personalized and effective.” A new overview on the potential uses and benefits of RWE has been published by PharmExec.com, authored (more…)

Now Recruiting: Health Economist, Cancer Care Ontario

To Apply Click Here The Pharmacoeconomics Research Unit is a research team that supports Cancer Care Ontario with timely, high quality, and relevant information to inform drug funding decisions.  The Unit plays an important role in assisting policy-makers and implementers with their health economics needs by conducting, evaluating and explaining (more…)

PhD Opportunity: The use of Health Technology Assessment in publicly funded health systems

The Faculty of Health at Dalhousie University is inviting applications to consider entry into Dalhousie’s PhD Health program. This is an exciting opportunity to work with Dr. W. Dominika Wranik in the area of Health Technology Assessment, with particular focus on the application of HTA to policy questions in publicly (more…)

FDA’s RWE Framework

Earlier in December the FDA released a new framework outlining how they will use Real World Evidence (RWE) and Real World Data (RWD) in decision making for new drugs and biologics.  Under the new framework, the FDA will use the following three criteria to evaluate RWE/RWD: 1. Whether the RWD are fit (more…)